|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000035464 |
|
最近更新日期: Date of Last Refreshed on: |
2020-08-12 00:36:06 |
|
注册时间: Date of Registration: |
1990-01-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
审核中(二)宏基因组测序技术在肺肉芽肿性疾病病原学诊断中的增值价值研究 |
|
Public title: |
Increnmental value of metagenomic sequencing in the etiological diagnosis of Pulmonary granulomatous diseases |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
宏基因组二代测序技术在肺肉芽肿性疾病病原学诊断中的增值价值研究 |
|
Scientific title: |
Increnmental value of metagenomic next sequencing in the etiological diagnosis of Pulmonary granulomatous diseases |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙雯雯 |
研究负责人: |
孙雯雯 |
|
Applicant: |
wenwen sun |
Study leader: |
wenwen sun |
|
申请注册联系人电话: Applicant telephone: |
+86 18721188229 |
研究负责人电话: Study leader's telephone: |
+86 18721188229 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sunwenwen_1583@163.com |
研究负责人电子邮件: Study leader's E-mail: |
sunwenwen_1583@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市杨浦区政民路507号 |
研究负责人通讯地址: |
上海市杨浦区政民路507号 |
|
Applicant address: |
No. 507, Zhengmin Road, Yangpu District, Shanghai |
Study leader's address: |
No. 507, Zhengmin Road, Yangpu District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
同济大学附属上海市肺科医院 |
||
|
Applicant's institution: |
Shanghai Pulmonary hospital affiliated to Tongji University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
K19-158 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市肺科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Commit-tee of shanghai pulmonary hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-11-05 00:00:00 |
||
|
伦理委员会联系人: |
桂涛 |
||
|
Contact Name of the ethic committee: |
tao gui |
||
|
伦理委员会联系地址: |
上海市杨浦区政民路507号 |
||
|
Contact Address of the ethic committee: |
No. 507, Zhengmin Road, Yangpu District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
同济大学附属上海市肺科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Pulmonary hospital affiliated to Tongji University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市杨浦区政民路507号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 507, Zhengmin Road, Yangpu District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
Target disease: |
Pulmonary infectious disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
评价mNGS在肺肉芽肿性病变活检组织学标本直接检出病原菌的效率,评价mNGS对肺部肉芽肿性疾病多学科诊断的增益。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficiency of mNGS in the direct detection of pathogenic bacteria in biopsy histological specimens of pulmonary granulomatous lesions, and to evaluate the gain of mNGS in the multidisciplinary diagnosis of pulmonary granulomatous diseases. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)本研究仅限于肺活检和手术标本,包括经支气管镜活检,CT或者超声引导下活检、手术活检(肺楔活检/肺叶切除术,开胸或胸腔镜辅助)。2)由病理科医生2名,复查玻璃片以确认肉芽肿性炎症的存在。3)记录纳入患者的临床信息作为基线信息,包括年龄、性别、患者的免疫状态、体温、全血细胞计数、血沉、C反应蛋白、痰涂片、微生物免疫学和血清学检测,以及是否进行了经验性的抗生素治疗。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) This study is limited to lung biopsy and surgical specimens, including bronchoscopic biopsy,CT or ultrasound-guided biopsy, surgical biopsy (pulmonary wedge biopsy/lobotomy, thoracotomy or video-assisted thoracoscopy).2) Glass slides were reviewed by 2 pathologists to confirm the presence of granulomatous inflammation.3) The clinical information of the included patients was recorded as baseline information, including age, sex, the patient's immune status, body temperature, CBC, erythrocyte sedimentation rate, C-reactive protein, sputum smear, microbial immunology and serological tests, and whether empirical antibiotic therapy was performed. |
||||||||||||||||||||||
|
排除标准: |
1)排除因组织标本质量不合格,无法进行所有研究所需检测者。2)排除因各种原因在治疗随访过程中中止随访或者失访者。3)排除合并严重心肺全身疾病者、HIV阳性者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Exclude those who cannot be tested for all studies due to unqualified tissue specimens.2) To exclude the follow-up suspension or loss of patients due to various reasons during the treatment follow-up.3) Exclude patients with severe cardiopulmonary systemic diseases and HIV-positive patients. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-10-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-10-01 00:00:00 至 To 2021-12-31 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
连续性纳入 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Continuous recruitment |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023.6后在Revman共享,研究完成后发表的论文 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
share in Resman since 2023.6 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
课题组保存和管理实验数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The research group saves and manages the experimental data |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |